Track topics on Twitter Track topics that are important to you
It’s not all doom and gloom for CAR-T immunotherapy. One week after the death of two patients in a trial by Juno Therapeutics, early-stage competitor bluebird bio has released positive interim results for its Phase 1 trial.
Original Article: Bluebird bio announces positive CAR-T resultsNEXT ARTICLE
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...